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Variation in lung function as a marker of adherence to oral and inhaled medication in 
cystic fibrosis 
White H, Shaw N, Denman S, Pollard K, Wynne S, Peckham DG. 
 
Study aim: The aim of this study was to characterise adherence in an adult population with CF 
and to investigate if variation in lung function was a predictor of adherence to treatment. 
 
Patients and methods: Patients aged ≥ 16 years from an adult CF centre undertook adherence 
measures by medication possession ratio (MPR) and self-report and were assigned to one of 
three adherence categories (<50%, 50-<80%, 80% and above) by their composite score (MPR). 
Ordinal regression was used to identify predictors of adherence including coefficient variation 
measures for forced expiratory volume in 1 second (FEV1), weight and C-reactive protein, 
measured up to 6 and 12 months.  
 
Results: MPR data for 106 of 249 patients [mean age 29.8 (±9.2) years] was retrieved, indicating 
a mean adherence of 63%. Coefficient of variation FEV1 was inversely related to adherence and 
was a univariate predictor of adherence (6 months: 0.92 [0.87-0.98] p= 0.005 and 12 months: 
0.94 [0.93-0.99], p=0.03]) and remained significant in the final models. The coefficient variation of 
weight and C-reactive protein were not predictive of adherence.  
 
Conclusions: Coefficient of variation FEV1 was identified as an objective predictor of adherence. 
Further evaluation of this potential marker of adherence is now required. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Introduction 
Advances in early diagnosis and treatment of cystic fibrosis (CF) have resulted in significant 
improvements in survival with many patients living into adulthood and middle age.[1,2] This 
success has been achieved through specialised multidisciplinary care in combination with intense 
treatment regimens which are time consuming and negatively impact on daily life. Poor 
adherence to treatment remains a significant problem, being as low as 40 to 50%.[3-7] 
Adherence problems can negatively influence health outcomes such as pulmonary 
exacerbations,[8] health related quality of life,[3] and healthcare costs;[6-9] trends that are also 
apparent across other respiratory diseases.[10-12]  
Consensus regarding the accurate measurement of adherence is lacking and has proved difficult 
in day-to-day practice. The use of subjective self-report, supported by objective measures 
including pharmacy collection, medication possession ratio and chipped hardware such as the i-
neb,[4]  are frequently used as part of good practice in reporting study findings. While all of these 
have inherent limitations,[7] objective physiological measures that might define adherence more 
accurately are lacking. 
Studies in other chronic diseases have recently highlighted the association between variation in 
physiological measures such as blood pressure [13-15] and immunosuppressive therapy [16] and 
adherence to medication. These provide objective measures, which may help to characterise 
poor adherence and trigger interventions to support better outcomes. Attention has focused on 
the variability of lung function as an improved predictor of lung decline in CF, above that of FEV1 
alone; the hypothesis being that it is a more sensitive marker that may reflect exacerbations, 
individual pulmonary variation, and adherence.[17]  
 In CF there is evidence that low rates of medication adherence are associated with increased 
pulmonary exacerbations.[8,18] Given the maintenance effect of medications such as nebuliser 
therapies on respiratory function, it is therefore plausible that poor adherence might be 
associated with greater variation in lung function. A variability measure that accounts for natural 
changes, exacerbations and individual variation over time might also provide greater predictive 
accuracy than studies that have shown an association between adherence and the single 
measure of baseline FEV1.[8] 
In the day to day management of patients with CF we have recognised apparent differences in 
the fluctuation of lung function, weight and infection markers in patients known to have poor 
adherence. Patterns in diseases such as these have only become apparent following 
implementation of a disease-specific electronic patient record containing rich clinical ‘real time’ 
diagnostic, biochemical, anthropometric, pulmonary function and pathology data.[19] This 
  
detailed longitudinal data which is routinely displayed graphically has provided a basis for testing 
whether variation indices might predict adherence within a population with CF. 
The aim of this study was to characterise adherence in a large adult population with cystic 
fibrosis and to test the hypothesis that increased variation in lung function was an indicator of 
poor adherence to treatment.  
 
Methodology 
 
Participants: Patients attending a large regional adult cystic fibrosis unit were recruited from 
December 2012 to August 2013. Participants were identified from an electronic register of 400 
patients, of 16 years and over, who had a diagnosis of CF as defined by the presence of a 
positive clinical phenotype with either two CF-causing mutations and/or two positive sweat tests. 
Participants were consecutively invited to participate in the study as they attended a routine out-
patient visit at a time of clinical stability. Patients attended every 2-3 months, in line with local 
policy. Exclusion criteria included pregnancy, neurological disease, malignancy and renal 
disease to avoid potential influences on adherence patterns.  
 
Measures:  
Forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) for the preceding 12 
months were recorded. Each was measured using a calibrated, compact spirometer (Vitalograph, 
UK) undertaken by an experienced physiotherapist, and using the best value from a series of at 
least three attempts in accordance with guidelines.[20] In addition, age, gender, genotype, 
baseline weight (kg), height (m), BMI (kg/m2), Vitamins A, D, E, C-reactive protein (CRP), number 
intravenous antibiotic treatment days within the last year were recorded.  
 
Coefficient of variation (CoV) for FEV1 was calculated by extracting all consecutive highest then 
lowest values for FEV1 for 6 and 12 months prior to baseline from the electronic health record. 
These time scales were chosen to align with pharmacy retrieval data CoV FEV1 (6 months) and 
to examine the impact of longer term patterns of variation on adherence CoV FEV1 (12 months).  
The total, mean and standard deviation of all values for FEV1 for each participant was calculated. 
The equation for coefficient of variation for FEV1 was then calculated according to standard 
deviation FEV1/mean FEV1. Coefficient of variation for weight and CRP were similarly examined.  
Adherence measures 
Pharmacy collection: Individual medications and prescribed days of treatment were retrieved 
from the EHR for the time period ≤ 6 months prior to the baseline index date; a time scale chosen 
  
to enable greater comparability with the level of self-reported adherence reported by the DMI-CF 
disease specific questionnaire.[7] Community pharmacy details were abstracted from the EHR 
and participants gave contact details for all other community pharmacies used within this time 
period. A letter of request was sent to all pharmacies together with a copy of the patient’s signed 
consent form requesting amount medication prescribed for ≤ 6 months prior to the baseline index 
date. Up to 2 repeat requests were made by phone to maximise prescription data return. 
Similarly for patients using the i-neb, the prescribed number of doses was also retrieved from the 
EHR and medication uptake then downloaded from the ineb ≤ 6 months prior to the baseline 
index date. Patient MPR was then adjusted for all medications prescribed during inpatient 
admission and any out-patient prescriptions issued from the ward. The MPR was calculated from 
at least two prescription collections for each individual medication and then averaged to obtain a 
composite MPR. Medication possession ratio (MPR) was calculated using the equation, 
medication dispensed divided by the number days medication prescribed, multiplied by 100. 
Adherence self-report: For each participant, a record of all routinely prescribed medications 
was generated at baseline from the electronic health record. All subjects completed a Disease 
Management Interview-CF (DMI-CF) self-report adherence questionnaire at baseline.[7] 
Percentage adherence to each prescribed medication was then calculated by dividing the 
reported dose by the prescribed dose for the each of the following medications and treatments; 
airway clearance, recombinant DNase, bronchodilators, inhaled steroids, pancreatic enzyme 
replacement therapy, nutrition, oral nutritional supplements or nasogastric/gastrostomy feed, 
vitamins, oral antibiotics, inhaled antibiotics and insulin. 
A composite adherence measure was calculated, omitting airway clearance, nutrition and insulin 
fpr self-report to enable a composite measure comparable to adherence by MPR. Composite 
adherence was calculated as the sum of all medications patients prescribed on the electronic 
record, divided by the total number of self-reported medications taken.  
Statistical analysis: Patient characteristics across medication and treatment adherence 
adherence (MPR), were compared using the Pearson chi–squared test (categorical variables) 
and the ANOVA (continuous variables). The Wilcoxon sign rank test was used to compare 
adherence by self-report with pharmacy.  
Patients were assigned to one of three categories according to adherence reported by MPR, [< 
50% adherence, 50 < 80% adherence and 80% and above]; a classification used in previous 
research in CF.[8] Ordinal regression was used to identify univariate predictors of adherence for 
testing in a multivariate model, using coefficient variation measures 6 and 12 months preceding 
baseline respectively. Genotype was defined as 3 categories (Delta F508 homozygous, Delta 
F508 heterozygous and ‘other’). Only univariate variables with a p value of <0.1 were used in the 
  
multivariate model. A forwards and backwards stepwise fashion process was used to construct a 
final model.  
Model evaluation: A chi2 score test was used to evaluate the proportional odds assumption and 
whether this was violated. Other methods used to check the assumption were the calculation of 
single score tests for each covariate and included the parallel lines assumption. Multi-collinearity 
was checked through calculation of the variance inflation factor (VIF) for each predictor. The 
likelihood ratio, score and Wald Tests were examined to determine the improvement of the MLR 
model over the intercept model.  
All analysis was implemented using SPSS 22 (University Chicago, Illinois). P values <0.05 were 
considered significant 
Ethical approval: The study received ethical approval from London City and East ethics 
committee [Ref: 12/LO/1776] and met all applicable institutional regulations at Leeds Teaching 
Hospitals NHS Trust, UK.   
 
Results  
Participant characteristics: Of 267 patients invited to participate in the study, 250 subjects 
were enrolled, 17 declined to participate (15 citing that they did not want to participate in this 
specific study and 2 citing that they did not wish to participate in studies in general). A further 
participant withdrew prior to analysis (n=249). Of this number, pharmacy refill data were obtained 
for 106 patients.   
With the exception of presence of diabetes, no differences were observed in characteristics 
between those with pharmacy refill data and those without (Table 1) Adherence by MPR was 
subsequently used in further analysis. 
 
 
 
 
 
 
 
  
Table 1. Participant characteristics for those with and without MPR refill data 
Characteristic MPR data 
available 
(n=106) 
No MPR data 
available 
(n=143) 
P 
value 
Age (years) 29.8 (±8.2) 29.5 (±9.8) 0.8 
Gender [n=male (%)] 46 (43.4%) 57 (39.9%) 0.6 
Genotype [n (%)] 
F508/F508    
F508/heterozygous 
Other 
                         
72 (68.0%)               
31 (29.2%)                       
3 (2.8%) 
                            
81 (56.7%)                      
51 (35.6%)                       
11 (7.7%)   
                   
0.1                            
 
Cystic fibrosis related diabetes   
[n=diabetic (%)            
17 (16%) 11 (7.7%)  0.04 
Microbiological status (n, %) 
Non-pseudomonas 
Pseudomonas 
Cepacia 
Mycobacterium abcessus 
                           
23 (21.7%)              
75 (70.8%)                     
5   (4.7%)                   
3   (2.8%) 
                              
32 (22.4%)                    
88 (61.5%)                   
12 (8.4%)                       
11 (7.7%) 
          
0.2
Weight (Kg) 64.0(±13.6) 64.3 (±13.7) 0.9 
BMI (Kg/m2) 22.4 (±3.6) 22.6 (±4.0) 0.6 
FEV1 (%) 60.2 (±24.5) 62.4 (±25.9) 0.5 
FVC (%) 78.7 (±22.1) 80.2 (±24.0) 0.6 
HbA1C (mmol/mol) 45.2 (±13.8) 44.5 (±12.1) 0.7 
Intravenous antibiotic treatment 
days (preceding 1 year period) 
29.1 (±40.0) 28.0 (±39.4) 0.8 
Number medications (n) 13.8 (±4.5) 13.1 (±4.7) 0.3 
Mean ±SD and 2 sample t-test for normally distributed variables: Pearson Chi2 for                                            
categorical variables 
 
Baseline characteristics are shown in Table 2. Participants were predominantly homozygous for 
the delta F508 mutation and had good nutritional status. Clinical and demographic characteristics 
were similar between adherence categories (MPR) (Table 2), but were significantly different for 
age, number medications, weight, BMI, Vitamin A, Vitamin D, Vitamin E.  
 
 
 
  
Table 2. Participant characteristics according to adherence measured by MPR 
 
 
Characteristic. 
Adherence 
 
Mean (SD or 
%) 
Total study 
population 
Adherence Categories 
 
 
Poor 
adherence 
<50% 
Moderate 
adherence 
50 <80% 
Good 
adherence 
>80% 
Difference 
across 
category 
     p-value 
Number [n (%)] 106 34 (32.1%) 38 (35.8%) 34 (32.1%) 0.86 
Age (Years) 29.8 (±8.2) 27.3(±6.8) 30.3 (±8.4) 31.8 (±8.7) 0.07 
Gender [(M/F) %] 60M (56.6%) 17M/17F    23/15 20/14 0.63 
Genotype [n (%)] 
   F508/F508 
   F508/heterozygous 
   Other 
   
 
72 (67.9%) 
31 (29.2%) 
3   (2.8%) 
 
 
24 (22.6%) 
9   (8.5%) 
1   (0.9%) 
 
 
23 (21.7%) 
13 (12.4%) 
2   (1.9%) 
 
 
25 (23.5%) 
9 (8.5%) 
0  
0.60 
Cystic fibrosis related 
diabetes 
 
17 (16%) 2 (1.9%) 10 (9.4%) 5 (4.7%) 0.06 
Microbiological status 
Non-pseudomonas 
Pseudomonas 
Cepacia 
Mycobacterium abcessus 
 
 
23 (21.7%) 
75 (70.8%) 
5   (4.7%) 
3   (2.8%) 
 
7   (6.6%) 
25 (23.6%) 
0   ( 
2   (1.9%) 
 
 
9   (8.5%) 
24 (22.6%) 
4   (3.8%) 
1   (0.9%) 
 
 
7   (6.6%) 
26 (24.5%)  
1   (0.9%) 
0   ( 
 
0.3 
Medications (n)  13.8 (±4.5) 11.8 (±4.1) 14.7 (±4.4) 14.7 (±4.4) 0.005 
Intravenous antibiotic 
treatment days (preceding 
1 year period)) 
29.0 (±40.1) 22.4 (±25.9) 35.0 (±51.4) 28.7 (±37.0) 0.44 
Weight (Kg) 64.6 (±13.6) 59.3 (±11.8) 66.5 (±13.2) 67.5 (±14.7) 0.02 
BMI (Kg/m2) 22.4 (±3.6) 20.8 (±2.8) 22.9 (±3.1) 23.4 (±4.3) 0.005 
FEV1 (%) 60.1 (±24.6) 62.7 (±24.2) 58.0 (±25.8) 60.3 (±24.0) 0.71 
FVC (%) 78.6 (±22.2) 79.3 (±23.1) 75.8 (±21.9) 81.5 (±21.7) 0.55 
HbA1C (mmol/mol) 45.2 (±13.8) 41.7 (±10.7) 49.1 (±18.3) 44.3 (±8.9) 0.07 
Vitamin A (µmol/l) 1.7   (±0.8) 1.4 (±0.60) 1.9 (±1.0) 1.8 (±0.53) 0.02 
Vitamin D (mmol/l) 66.6 (±26.0) 51.8 (±23.3) 72.9 (±26.3) 74.0 (±22.7) 0.001 
Vitamin E (mg/l) 28.2(±10.7) 22.4 (±10.1)  29.9 (±9.6) 31.7 (±10.6) <0.001 
 
*  Mean ±SD and ANOVA for normally distributed variables: Pearson Chi2 for categorical variables 
 
 
Adherence measures: Pharmacy refill collection was retrieved for 106 of the 249 participants 
and 249 completed the DMI-CF self-report adherence questionnaire. Comparison of the two 
adherence measures revealed significant differences for rDNase, inhaled steroids, oral 
antibiotics, pancreatic enzyme supplementation, nutritional supplements and vitamins. MPR 
reported adherence was consistently below that of self-reported adherence for all medications 
and treatments (Fig.1). For three aspects of adherence an accurate MPR could not be 
  
calculated, either due to lack of verifiable data (nutrition and airway clearance) or highly variable 
dosage (insulin). The composite score for adherence (MPR) was 63.4% (±25.3) and for self-
report 79.9% (±19.7) respectively (Fig. 1), with only 32.1% of subjects lying within the highest 
category adherence (Table 2). For 3 patients a score of zero was recorded for MPR. For one 
patient this a comparable score of 3% was obtained for self-report. The remaining 2 patients had 
no further adjustment to MPR, after checking for in-patient admission and prescriptions issued at 
end of in-patient stay.   
 
FIGURE 1 Adherence measured by medication possession ratio (MPR) and self-report. 
Composite self-reported adherence calculated only from medications and treatments with a 
corresponding MPR value 
 
 
Variation measures : Mean coefficient of variation for FEV1 ,calculated from the preceding 6 
month period, was 11.4% (±7.4%) and CoV weight and CRP were 2.1 % (±1.4%) and 35.8% 
(±41.0%) respectively. These patients had on average 4.67% higher CoV FEV1 and 7.3% higher 
CoV CRP compared to those with good adherence. CoV for weight remained stable across MPR 
adherence categories. (Fig. 2).Values were similar using CoV FEV1 (12 month preceding period), 
[CoV FEV1 11.4% (±7.2%), CoV weight 2.9 % (±2.1%), and CoV CRP 46.7% (±46.4%)]. In total, 
38/106 (35.8% participants with MPR data) had stable CRP of < 10mg/L throughout the period of 
the study and zero fluctuation.  
 
 
  
FIGURE 2 Relationship between coefficient variation measures and adherence, measured by 
medication possession ratio. CoV: coefficient of variation; FEV1: forced expiratory volume in 1 s; 
CRP: C-reactive protein. 
 
 
 
Univariate and multivariate analysis: In an unadjusted ordinal model, predictors of adherence 
(MPR) were age, number of medications prescribed, body mass index, CoV FEV1 (6 months 
preceding), Vitamin D and E (Table 3). Following a stepwise regression, CoV FEV1, number of 
medications, and BMI remained significant (Fig 3). The odds of being in a higher adherence 
category increased with every unit of BMI, each 1% reduction in CoV FEV1, and each additional 
medication [Fig. 3]. This was replicated using CoV FEV1 (12 months preceding). 
 
 
 
 
 
 
 
 
 
  
Table 3. Univariate analysis of predictors of adherence measured by MPR  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
                                                  
*Test of parallel l ines non-significant for al l  variables (MPR)  
 
        
  Adherence (MPR) 
Characteristic  p-
value 
Odds ratio [CI] 
Age (years) 0.03  1.05   [1.01-1.11] 
Gender  
 
0.46  1.31   [0.64-2.65]   
Genotype 
Delta F508 homozygous 
Delta F508 
heterozygous 
Other 
 
0.55 
0.58  
 . 
 
 
 1.93 [0.22-16.81] 
 1.87 [0.20-17.87]  
 (Reference) 
Number medications (n) 0.008 1.12  [1.03-1.22] 
Intravenous antibiotics in 
preceding year (no. 
days) 
0.61 1.00  [0.99-1.01] 
Body mass index (kg/m2) 0.004 1.18  [1.05-1.32] 
Baseline FEV1 (%) 0.68 1.0    [0.98-1.01] 
HbA1C  0.55 1.01  [0.98-1.03] 
6 month preceding  
     CoV FEV1 0.005 0.92  [0.87-0.98] 
     CoV Weight 0.60 0.94  [0.73-1.20] 
     CoV CRP 0.80 1.00  [0.99-1.01] 
12 month preceding  
     CoV FEV1 0.02 0.94  [0.89-0.99] 
     CoV Weight 0.29 0.92  [0.79-1.07] 
     CoV CRP 0.14 1.00  [0.99-1.00] 
Vitamin A  0.09 1.57  [0.93-2.65] 
Vitamin D  0.001 1.02  [1.01-1.04] 
Vitamin E  <0.001 1.07  [1.03-1.11] 
FEV1 decline (%)  0.91 1.00  [0.98-1.03] 
Diagnosis of CFRD   0.40  0.65 [0.25-1.70]   
(Reference) 
Microbiological status 
Non pseudomonas 
Pseudomonas 
Cepacia    
Mycobacterium 
abcessus 
  
0.22 
0.20 
0.19 
 
 
4.9 [0.38-62.5]  
5.1 [0.43-59.7]  
6.9 [0.37-129.5] 
(Reference)  
 
  
FIGURE 3 Final models of inverse and positive predictors of adherence by medication 
possession ratio (MPR) using the coefficient of variation of the forced expiratory volume in 1 s 
(CoV FEV1). a) Final model using data from preceding 6 months. Score test for the proportional 
odds assumption: Chi-squared=13.6, p=0.06. Goodness of fit test of overall model (likelihood 
ratio): Chi-squared(7)=28.6, p<0.0001. Pseudo R2 (Nagelkerke) =27.4. b) Final model using data 
from preceding 12 months. Score test for the proportional odds assumption: Chi-squared=10.2, 
p=0.18. Goodness of fit test of overall model (likelihood ratio): Chi-squared(7)=25.1, p<0.0001. 
Pseudo R2 (Nagelkerke)=27.1. Both models were adjusted for the presence of cystic fibrosis-
related diabetes and microbiological status. 
a)                                                                   b) 
 
 
Discussion 
 
This is the first study to demonstrate a significant inverse relationship between coefficient of 
variation FEV1 (CoV FEV1) and adherence to treatment in adults with cystic fibrosis. This was 
true of values based on lung function measures taken up to 6 months and 12 months preceding 
baseline. Similar inverse relationships in physiological parameters have recently been reported in 
other chronic diseases. For example the coefficient of variation of blood pressure, renal function 
and peak flow increased with reduced adherence to antihypertensive, immunosuppressant and 
asthma therapy respectively.[13-16, 21] These observations suggest that variability in 
physiological parameters may be an important marker of adherence to treatment in chronic 
disease more generally.  
 
The underlying mechanism for the predictive value of CoV FEV1 was not addressed in the current 
study but may reflect poor disease control, reduced adherence to physiotherapy and nebulised 
therapy. Delays in patients seeking medical intervention at times of exacerbation may also be 
  
important, as it is not infrequent for patients with poor adherence to dramatically improve their 
lung function during hospital admission, resulting in larger variation in lung function than is seen 
in those who enter treatment at an earlier stage.  
It can be argued that in patients with asthma, where lung function is routinely used as an 
objective measure of airways obstruction, the disease is also characterised by a high degree of 
variability demonstrated by peak flow (PF) and FEV1 falling abruptly on treatment withdrawal. In 
contrast, CF is associated with endobronchial infection, mucus retention and to a lesser extent 
airway hypersensitivity. The withdrawal of inhaled corticosteroids in patients with CF without 
asthma appears to have no impact on change in lung function, antibiotic usage and rescue 
bronchodilator. [22] It suggests that the variation in lung function in this study is not explained by 
the diurnal variation or hyper responsiveness reported in asthma.  
Weight loss may occur as a result of reduced adherence to pancreatic and oral supplements and 
increased energy expenditure during episodes of pulmonary infection. Surprisingly, the 
coefficient variation of weight was consistent in all groups, with high levels of reported adherence 
to nutritional recommendations and pancreatic enzyme replacement therapy in patients with a 
stable BMI in mid-normal range (22.5-22.8kg/m2). These findings, and the inclusion of BMI as a 
positive predictor of adherence in the final model, may reflect better patient engagement with 
nutritional recommendations. Similarly the inflammatory marker, CRP was not a predictor of 
adherence, and may in part have been due to normal CRPs in many of the patients and routine 
early antibiotic intervention prior to elevation in CRP.  
Age was a significant positive predictor of MPR adherence in the univariate but not final model. It 
confirms the complexity of adherence measurement and the difficulties in defining a single 
marker alone. While reduced adherence is well documented during the transition from childhood 
into adolescence and young adulthood,[5,9,23] the impact of age as adulthood progresses is less 
clear. Quittner et al examined medication possession ratio in 3,827 patients and showed a 
decline in adherence that stabilised in the fourth decade of life; a trend replicated by others.[9]  
Conversely studies of smaller sample sizes have indicated a positive impact of age [24] whilst 
acknowledging the wide variation between individuals. Our own results indicate that adherence 
improves with age and suggests that interventions to improve adherence should be targeted 
towards those in early adulthood.   
 
A significant predictor of adherence in the overall models were number of medications 
prescribed. This relationship was replicated when adherence was measured according to self-
report [Supplementary Table 1]. As adherence category improved, patient medications rose from 
10 to 14 medications daily. This positive association contrasts with previous reports that 
  
associate treatment burden with barriers to adherence,[25,26] but agrees with findings by 
Quittner et al who reported a positive association between medication regimen complexity and 
adherence.[9]  However their proposal that a more complex regimen may be a proxy for disease 
severity and a greater willingness to undertake prescribed medication, was not borne out in our 
own study. Whilst an upward trend in disease severity was observed, this was not significant, nor 
was there a difference in intravenous antibiotic treatment days different across adherence 
categories. Others have also shown that high treatment burden is independent of disease 
severity.[27] Why increased medication may be associated with improved adherence in our study 
is therefore unclear. We hypothesise that increase treatment burden may reflect improved clinical 
control especially as it is our practice to stop or change medications in partnership with patients 
in response to poor treatment uptake. It is not infrequent that the team stop all treatment in 
patents with very poor adherence in order to start again, adjusting therapy accordingly. Another 
possibility is that some individuals are “resilient” and have developed specific coping strategies 
that enable them to perform this complex regimen on a regular basis.   
 
Adherence measured by MPR was consistently below that measured by self-report with a mean 
discrepancy of 14% for the composite scores. Similar trends are consistent in the literature, 
although there is little consensus as to how it might best be addressed in reporting data. Quittner 
et al. have advocated triangulation of data with at least 2 measures employed, integrated through 
regression analysis into a single index.[7] We chose to report  adherence by MPR and self-report 
measures, noting that neither provide a definitive measure of adherence. The discrepancies 
observed agree with previous reports in adult cohorts; physiotherapy being the least frequently 
adhered to treatment (49%), and pancreatic enzyme replacement therapy the best (91%).[28] In 
general adherence to respiratory treatments was poorer than to nutritional therapies suggesting 
that challenges in improving treatment uptake have changed little in 20 years. 
 
Adherence (MPR) was a composite measure assimilated from core medications that were 
present on an established questionnaire, the DMI-CF.[7] It.is probable that each medication or 
treatment has a different weighting of importance both within and between patients. In turn this 
highlights the complexity of developing a valid adherence index measure for wider use. It is also 
likely that the composite measure used within this study might be reduced to contain fewer 
medications, although consensus is lacking as to what this might be.  
 
The study has several limitations inherent to all studies examining adherence through cross-
sectional design and reliant on current methods of adherence measure. Firstly, adherence is 
known to be a fluid measure, changing over time and by treatment component.[29,30] 
  
Measurement is complex and although MPR is considered a more accurate measure of 
adherence than self-report, it has inherent limitations associated with changes in prescription and 
medication carryover. The former was partially accounted for within the study by accurate 
prescription data documented within the EHR system against which prescription collection could 
be aligned. For treatments such as pancreatic enzyme replacement therapy where patients self-
titrate against differing snack and meal content, this is less useful and whilst average daily intake 
of PERT was obtained and documented, error is likely. MEMS data, considered the ‘gold 
standard’ can provide greater accuracy,[31] but has inherent costs and its own bias if doses are 
removed but not consumed. It has led to a recognition that   measurement technique and that 
studies should incorporate more than one measure.[7] Our own results demonstrate 
concordance between both measures of adherence and enabled patterns of objective measures 
of adherence to emerge that can inform future adherence interventions and predictive variables 
that can be further explored to aid evaluation.  
 
The measure of lung function itself is also prone to error. We sought to minimise this through a 
standardised approach to measurement of pulmonary function within the clinic setting, where 
trained physiotherapists undertook all measures in line with current guidance.[20] In healthier 
subjects FEV1 is also known to lack sensitivity in detecting early change, when in fact lung 
damage is present.[32] The threshold for variation to occur may therefore be different in early 
compared to moderate and late disease despite similar levels of poor adherence and this 
requires further study. In future research the more sensitive lung function clearance index may 
add further value and accuracy in determining smaller changes in lung function 
measurement.[33] 
 
The study also has a number of strengths. Electronic clinical records that contain data captured 
in ‘real time’ enabled accurate extraction of all FEV1 data points for calculation of CoV FEV1. [17] 
As a measure CoV FEV1 provides an average of lung function dispersion values over time, 
making use of longitudinal data that can be incorporated into a single index. This is considered 
important in future studies, in a move away from ‘snapshot’ values that may contribute to bias. 
Importantly the final model was robust meeting the validity criteria for ordinal regression and 
achieving a model of good fit.  
 
Conclusion:  Coefficient of variation FEV1 is a significant predictor of adherence. This novel 
marker of adherence requires further evaluation across treatment regimens and duration of 
treatment. 
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Supplementary Table 1 Univariate predictors of self-reported adherence 
 
 
 
 
 
 
                      Adherence (self-report) 
Characteristic  p-value Odds ratio [CI] 
Age (years) 0.002 1.05    [1.02-1.08] 
Gender  
 
0.88 1.04    [0.63-1.72] 
Reference = female 
Genotype 
Delta F508 
homozygous 
Delta F508 
heterozygous 
Other 
 
0.43 
 
0.30 
 
1.53    [0.53-4.37] 
 
1.78    [0.60-5.31] 
 
(reference) 
Number medications 
(n) 
<0.001 1.15    [1.09-1.23] 
Intravenous 
antibiotics in 
preceding year (no. 
days) 
0.61 1.00    [1.0-1.01] 
Body mass index 
(kg/m2) 
0.58 1.02    [0.95-1.09] 
Baseline FEV1 (%) 0.82 1.00    [0.99-1.01] 
HbA1C  0.01 1.03    [1.01-1.05] 
6 month preceding   
   CoV FEV1 0.09 0.95    [0.89-1.00] 
   CoV Weight 0.10 0.79    [0.61-1.04] 
   CoV CRP 0.90 1.00    [0.99-1.00] 
12 month preceding   
   CoV FEV1 0.03 0.96    [0.93-0.99] 
   CoV Weight 0.44 0.96    [0.85-1.07] 
   CoV CRP 0.33 1.00    [1.00-1.01] 
Vitamin A  0.16 1.30    [0.90-1.88 
Vitamin D  <0.001 1.03    [1.02-1.04] 
Vitamin E  0.03 1.03    [1.00-1.05] 
FEV1 decline (%)  0.91 1.00    [0.98-1.01] 
Diagnosis of CFRD   0.76 0.89    [0.40-1.96] 
(Reference)  
Microbiological status 
Non pseudomonas 
Pseudomonas 
Cepacia 
Mycobacterium 
abcessus 
  
0.72 
0.97 
0.60 
 
 
1.2   [0.39 -3.97] 
1.02 [0.35-3.00]  
1.47 [0.35-6.20]  
 
(Reference) 
